Global Proteomic Biomarker Market Size To Exceed USD 16.5 Billion By 2035 | CAGR of 9.97%
Category: HealthcareGlobal Proteomic Biomarker Market Size To Exceed USD 16.5 Billion By 2035
According to a Research Report Published by Spherical Insights & Consulting, the Global Proteomic Biomarker Market Size is Expected to Grow from USD 5.8 Billion in 2024 to USD 16.5 Billion by 2035, at a CAGR of 9.97% during the forecast period 2025-2035.
Get more details on this report -
Browse 298 Market Data Tables And 45 Figures Spread Through 130 Pages and In-Depth TOC On the “Global Proteomic Biomarker Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Reagents, Instruments, and Services), By Application (Drug Discovery, Diagnostics, Personalized Medicine, Clinical Research, and Others), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Diagnostic Laboratories, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.” Get Detailed Report Description Here:https://www.sphericalinsights.com/reports/proteomic-biomarker-market
By Product Type, By Application, By End-User, By Region and COVID-19 Impact Analysis
The proteomic biomarker market refers to the market emphasizing the identification, development, and use of protein-based biomarkers for applications, like disease diagnostics, drug discovery, and personalized medicine. Proteomic biomarker provides the key information about the dynamic nature of proteins, including their functionality, post-translational modifications, interaction with other biological molecules, and response to environmental factors. Integration of AI and machine learning is revolutionizing the proteomic biomarker landscape and bringing breakthroughs in identifying and validating biomarkers, thereby driving the development of new diagnostic tools and therapies. The growing prevalence of chronic diseases is anticipated to drive the market demand as there is a growing development of novel biomarker panels for improving early disease diagnosis and therapeutic response. Further, the development of personalized medicine by facilitating the detection of protein biomarkers and technological advancements is propelling the market growth. However, the high cost of proteomics R&D and the limited accessibility of sophisticated protein analysis equipment are challenging the market growth.
The reagents segment held a significant market share in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the product type, the proteomic biomarker market is divided into reagents, instruments, and services. Among these, the reagents segment held a significant market share in 2024 and is projected to grow at a substantial CAGR during the forecast period. An upsurging innovation in reagent formulations and the development of specialized kits for specific biomarkers are propelling the proteomic biomarker market growth.
The drug discovery segment dominated the market with the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the application, the proteomic biomarker market is divided into drug discovery, diagnostics, personalized medicine, clinical research, and others. Among these, the drug discovery segment dominated the market with the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Proteomics is a valuable approach for drug target discovery, accelerating discovery processes. Integration of proteomics into drug development with reduced time and cost associated with drug discovery is propelling the market.
The pharmaceutical & biotechnology companies segment accounted for the dominant market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.
Based on the end-user, the proteomic biomarker market is divided into pharmaceutical & biotechnology companies, academic & research institutes, diagnostic laboratories, and others. Among these, the pharmaceutical & biotechnology companies segment accounted for the dominant market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Collaborations between pharmaceutical firms and research organizations for facilitating the development of novel biomarkers and therapeutic pipeline integration are driving the market growth of proteomic biomarker.
North America is expected to hold the majority share of the global proteomic biomarker market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global proteomic biomarker market during the forecast period. The presence of advanced healthcare infrastructure, robust research & development activities in the region is promoting the proteomic biomarker market growth. Advancements in mass spectrometry, along with increasing emphasis on research in personalized medicine, further propel the market.
Asia Pacific is anticipated to grow at the fastest pace in the global proteomic biomarker market during the forecast period. Development in next-generation sequencing technologies for providing high-precision protein analysis and mass spectrometry is propelling the market growth. The increasing healthcare expenditures and expanding research capabilities are driving the proteomic biomarker market.
Europe is anticipated to hold a significant share of the proteomic biomarker market during the predicted timeframe. The increasing adoption of proteomics technology by the pharmaceutical companies is driving the market growth. The presence of well-established healthcare systems and the adoption of advanced diagnostic technologies in the region are also driving the proteomic biomarker market.
Major vendors in the global proteomic biomarker market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Waters Corporation, Bruker Corporation, GE Healthcare, PerkinElmer, Inc., Merck KGaA, Shimadzu Corporation, Siemens Healthineers, Roche Diagnostics, Qiagen N.V., Luminex Corporation, Illumina, Inc., Becton, Dickinson and Company, Caprion Proteomics Inc., Meso Scale Diagnostics, LLC., Proteome Sciences plc, Olink Proteomics, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the proteomic biomarker market based on the below-mentioned segments:
Global Proteomic Biomarker Market, By Product Type
- Reagents
- Instruments
- Services
Global Proteomic Biomarker Market, By Application
- Drug Discovery
- Diagnostics
- Personalized Medicine
- Clinical Research
- Others
Global Proteomic Biomarker Market, By End-User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Diagnostic Laboratories
- Others
Global Proteomic Biomarker Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?